-
Placenta accreta can represent a real clinical conundrum, especially if it is unrecognized before delivery.
-
A few studies have suggested that we tend to underestimate blood loss during deliveries and cesarean sections. A group from Louisiana State University has addressed this issue again in a very clever way.
-
-
Curtis and colleagues from the University of Alabama at Birmingham measured the rate of hip fracture among women who discontinued bisphosphonate therapy compared with women who remained on treatment.
-
The Women's Iinternational Study of Long Duration Oestrogen after the Menopause (WISDOM) trial was a randomized, controlled trial in the United Kingdom, Australia, and New Zealand, of 3721 women aged 50-69 treated with either combined 0.625 mg conjugated estrogens and 2.5/5.0 mg medroxyprogesterone, or placebo. The original plan was to randomize 22,300 women to the study that would last 10 years.
-
One of the most common and poignant questions an ovarian cancer patient asks upon learning of her diagnosis is, "How did I get this?
-
In this issue: FDA warning on topical anesthetics; antipsychotics increase sudden cardiac death; the step up vs step down debate; treating pain, fatigue, mood, and sleep in fibromyalgia; FDA Actions.
-
Think about the last five women who have entered your examination room. How many of them have had genital herpes simplex virus Type 2 (HSV-2) infection?
-
How can Hispanic men be reached with an HIV prevention message? It's time to spread the word. While Hispanics/Latinos comprise 15% of the U.S. population, they accounted for 17% of all new HIV infections occurring in the United States in 2006.
-
When the female condom first gained Food and Drug Administration (FDA) approval in 1993, women's health advocates hailed it as a form of female-controlled protection; however, use of the method has been underwhelming among American women since its introduction.
